We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Evofem Biosciences Inc | NASDAQ:EVFM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.4782 | 0.465 | 0.468 | 0 | 01:00:00 |
Delaware | 20-8527075 | |||||||
(State or other jurisdiction of
incorporation or organization) |
(I.R.S. Employer
Identification No.) |
Adam C. Lenain, Esq.
Melanie Ruthrauff Levy, Esq.
Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
3580 Carmel Mountain Road, Suite 300
San Diego, CA 92130
Tel: (858) 314-1500
|
Alexander A. Fitzpatrick, Esq.
General Counsel
Evofem Biosciences, Inc.
12400 High Bluff Drive, Suite 600
San Diego, CA 92130
Tel: (858) 550-1900
|
|||||||
________________________________________________________________ |
Large accelerated filer ☐
|
Accelerated filer ☐
|
|||||||
Non-accelerated filer ý
|
Smaller reporting company ý
|
|||||||
Emerging growth company ☐
|
Title of securities
to be registered
|
Amount To be
registered (1)
|
Proposed maximum
offering price per share |
Proposed maximum
aggregate offering price |
Amount of
registration fee |
||||||||||
Common Stock, $0.0001 par value per share |
3,254,061 (2)
|
$2.73 (4)
|
$8,883,586.53 | $969.20 | ||||||||||
Common Stock, $0.0001 par value per share |
1,000,000 (3)
|
$2.73(4)
|
$2,730,000.00 | $297.84 |
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (“Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock that become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant’s receipt of consideration that results in an increase in the number of the outstanding shares of the Registrant’s Common Stock.
|
(2) | Represents additional shares of Registrant’s Common Stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Plan as of the date of this Registration Statement by operation of the plan’s “evergreen” provision. |
(3) | Represents additional shares of Registrant’s Common Stock reserved for issuance under the 2019 Employee Stock Purchase Plan as of the date of this Registration Statement by operation of the plan’s “evergreen” provision. |
(4) | Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee based on the average of the high and low prices of the Registrant’s Common Stock as reported on The Nasdaq Capital Market on January 27, 2021. |
Incorporated by Reference | |||||||||||||||||||||||||||||
Exhibit No. | Exhibit Title | Herewith | Form | File No. | Date Filed | ||||||||||||||||||||||||
4.1 |
10-K
(Exhibit 3.1) |
001-36754 | 02/26/2018 | ||||||||||||||||||||||||||
4.2 |
8-K
(Exhibit 3.2) |
001-36754 | 01/17/2018 | ||||||||||||||||||||||||||
4.3 |
10-K
(Exhibit 4.1) |
001-36754 | 02/26/2018 | ||||||||||||||||||||||||||
4.4 |
8-K
(Exhibit 4.1) |
001-36754 | 03/25/2020 | ||||||||||||||||||||||||||
5.1 | X | ||||||||||||||||||||||||||||
23.1 | X | ||||||||||||||||||||||||||||
23.2 | Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1). | X | |||||||||||||||||||||||||||
24.1 | Power of Attorney (included on signature page). | X | |||||||||||||||||||||||||||
99.1 # |
8-K
(Exhibit 10.1) |
001-36754 | 05/12/2020 | ||||||||||||||||||||||||||
99.2 # |
8-K
(Exhibit 10.2) |
001-36754 | 06/05/2019 |
# Indicates a management contract or compensatory plan.
|
By: | /s/ Saundra Pelletier | ||||
Name: | Saundra Pelletier | ||||
Title: |
President and Chief Executive Officer
|
Signature | Title | Date | ||||||||||||
/s/ Saundra Pelletier |
President and Chief Executive Officer and Director
(Principal Executive Officer)
|
January 28, 2021 | ||||||||||||
Saundra Pelletier | ||||||||||||||
/s/ Justin J. File |
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
|
January 28, 2021 | ||||||||||||
Justin J. File | ||||||||||||||
/s/ William Hall, Ph.D. | Chairman of the Board | January 28, 2021 | ||||||||||||
William Hall, Ph.D., M.D. | ||||||||||||||
/s/ Gillian Greer, Ph.D. | Director | January 28, 2021 | ||||||||||||
Gillian Greer, Ph.D. | ||||||||||||||
/s/ Kim P. Kamdar, Ph.D. | Director | January 28, 2021 | ||||||||||||
Kim P. Kamdar, Ph.D. | ||||||||||||||
/s/Tony O’Brien | Director | January 28, 2021 | ||||||||||||
Tony O’Brien | ||||||||||||||
/s/ Colin Rutherford | Director | January 28, 2021 | ||||||||||||
Colin Rutherford | ||||||||||||||
/s/ Lisa Rarick | Director | January 28, 2021 | ||||||||||||
Lisa Rarick |
1 Year Evofem Biosciences Chart |
1 Month Evofem Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions